Jiangsu Hengrui Pharmaceuticals Co., Ltd.
600276 · Shanghai Stock Exchange (SSE) · Pharmaceuticals
公司简介
Jiangsu Hengrui Pharmaceuticals is one of China's largest innovative pharmaceutical companies, with a major focus on oncology, anaesthesia, contrast agents, and metabolic disease therapeutics, and an extensive pipeline of novel small molecules and biologics in clinical development. The company has been investing heavily in drug innovation and has received approvals for several products in regulated international markets including the US and Europe. It is a privately controlled company headquartered in Lianyungang, Jiangsu Province.
| 交易所 | Shanghai Stock Exchange (SSE) |
| 股票代码 | 600276 |
| 行业 | Pharmaceuticals |
| 参考市值 美元 | $25.00B |
| 网站 | 访问官网 |
实时报价
正在加载实时价格……
| 市值 | |
| 当日区间 | |
| 52周区间 |
购买渠道
在其本地市场（Shanghai Stock Exchange (SSE)），可通过以下提供该交易所准入的全球券商进行投资：
- Interactive Brokers — Direct access to 90+ markets worldwide, including many emerging exchanges.
- Saxo Bank — Multi-market access across Asia, Europe and the Middle East.
- Charles Schwab (Global) — Foreign ordinary shares on select markets; US-listed ADRs and ETFs.
- Fidelity International Trading — International stock trading on a number of developed and emerging markets.
- Shanghai Stock Exchange — 官方交易所上市信息
仅为准入信息参考，不构成推荐或购买要约。请向您的券商确认资格、费用及当前可用性。
China的其他公司
公司数据及任何实时价格均为参考性质，可能存在延迟或不准确，仅供研究参考，不构成投资建议。请以交易所、公司公告及您的券商信息为准。